Navigation Links
FluoroMax multiwavelength capability


Introduction
Simultaneously monitoring the levels of relevant metabolites and cell parameters is necessary to properly assess the effectiveness of drugs on living cells. The FLUOROMAX spectrofluorometer allows the user to monitor up to eight wavelength-pairs of emission and excitation wavelengths. Coupling this capability with the proper probes can produce a real-time analysis of unfolding biological processes.


Results
One research application that used simultaneous observation of multiple wavelength-pairs was performed by M. Kimura, et al., at the University of Medicine and Dentistry of New Jersey. 1 Their evaluation of Thapsigargin, a hypertensive drug, was performed on a FLUOROMAX spectrofluorometer. The results demonstrated that the effect of the drug in human platelets was not limited to the elevation of the Ca2+ but produced substantial changes in the overall ionic balance.

Figure 1 shows a sample screen display taken from DATAMAX (FLUOROMAX software for Windows). Note how DATAMAX makes the monitoring of up to eight wavelengthpairs a simple matter of selection.


Conclusion
FLUOROMAX, with DATAMAX software, allows the user to monitor wavelengthpairs to characterize processes in living cells and other biological systems. The measurement is feasible in real time because of the FLUOROMAX spectrofluorometers ability to scan rapidly (up to 200 nm s1).


1 Kimura, M.; et al. J. Physiol. 1993, 494, 113.


back to top
'"/>

Source:


Page: All 1

Related biology technology :

1. Photoluminescence Spectroscopy of Quantum Dots, monitored by the Spex FluoroMax
2. Near IR capability of the FluoroLog
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... , Jan. 17, 2017  An international ... of Medicine and St. Boniface Hospital Albrechtsen Research ... peripheral neuropathy, an unmet health need affecting nearly ... Journal of Clinical Investigation, their results identify small ... prevent and reverse neuronal injury in animal models ...
(Date:1/17/2017)... LEXINGTON, Mass. , Jan. 17, 2017   ... clinical stage biopharmaceutical company developing innovative inhaled therapies to ... candidate for treating fungal infections in the lungs of ... Infectious Disease Product" (QIDP) by the U.S. Food & ... , which is designed to speed the development of ...
(Date:1/17/2017)... 17, 2017  Only nine percent of U.S. consumers ... while only 16 percent believe health insurance companies do, ... 36 percent of U.S. adults believe health care providers ... compared to hospitals (23%). "We are in ... Wendy Salomon , vice president of reputation management and ...
(Date:1/17/2017)... ... January 17, 2017 , ... Pono Ola , a mind-body wellness firm ... today the official launch of its much-anticipated Pono Board: a re-invented fitness and anti-fatigue ... development for over a year, the patented Pono Board is the world’s only exercise ...
Breaking Biology Technology:
(Date:1/18/2017)... , Jan. 18, 2017 MedNet ... that supports the entire spectrum of clinical research, ... another record-breaking year for the organization in terms ... in MedNet,s eClinical products and services. The company,s ... marketplace success of iMedNet ...
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology market is ... 19.4% from 2016 to 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):